[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20055880L - Memantin orale doseringsformer - Google Patents

Memantin orale doseringsformer

Info

Publication number
NO20055880L
NO20055880L NO20055880A NO20055880A NO20055880L NO 20055880 L NO20055880 L NO 20055880L NO 20055880 A NO20055880 A NO 20055880A NO 20055880 A NO20055880 A NO 20055880A NO 20055880 L NO20055880 L NO 20055880L
Authority
NO
Norway
Prior art keywords
memantine
dosage form
dosage forms
oral dosage
memantine oral
Prior art date
Application number
NO20055880A
Other languages
English (en)
Inventor
Bruce A Firestone
John J Vander Zanden
Janet K Cheetham
Richard Kurjan
Teresa H Kuan
Ching-Ming Chang
J Abraham M Espiritu
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NO20055880L publication Critical patent/NO20055880L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det beskrives oral doseringsform som inneholder mellom 1 mg og 100 mg av memantin, hvor doseringsformen ikke inneholder 10 mg av memantin eller 20 mg av memantin, og hvor doseringsformen ikke blir tillaget av pasienten eller en person som administrerer drogen til pasienten som oppdeler doseringsformen som inneholder en større dose av memantin. Andre aspekter vedrører farmasøytiske produkter som omfatter de nevnte doseringsformer og fremgangsmåter for a administrere memantin og behandle sykdom med nevnte doseringsform.
NO20055880A 2003-06-16 2005-12-12 Memantin orale doseringsformer NO20055880L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47897903P 2003-06-16 2003-06-16
PCT/US2004/018506 WO2004112768A1 (en) 2003-06-16 2004-06-10 Memantine oral dosage forms

Publications (1)

Publication Number Publication Date
NO20055880L true NO20055880L (no) 2005-12-28

Family

ID=33539133

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055880A NO20055880L (no) 2003-06-16 2005-12-12 Memantin orale doseringsformer

Country Status (16)

Country Link
US (2) US20040254251A1 (no)
EP (1) EP1631273A1 (no)
JP (1) JP2006527774A (no)
KR (1) KR20060033727A (no)
CN (1) CN1805737A (no)
AU (1) AU2004249151A1 (no)
BR (1) BRPI0411451A (no)
CA (1) CA2529535A1 (no)
IL (1) IL172233A0 (no)
MX (1) MXPA05012810A (no)
NO (1) NO20055880L (no)
PL (1) PL378902A1 (no)
RU (1) RU2006101225A (no)
TW (1) TW200524639A (no)
WO (1) WO2004112768A1 (no)
ZA (1) ZA200509379B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
FR2855344A1 (fr) * 2003-05-22 2004-11-26 France Telecom Systeme de gestion de contexte pour un reseau comportant un ensemble heterogene de terminaux
EA011290B1 (ru) * 2004-06-17 2009-02-27 Мерц Фарма Гмбх Унд Ко. Кгаа Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
AU2005309601A1 (en) * 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
NZ555693A (en) 2004-12-27 2010-10-29 Eisai R&D Man Co Ltd Matrix type sustained-release preparation containing donepezil
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
WO2006118265A1 (ja) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 抗痴呆薬を含有する組成物
WO2007095424A1 (en) * 2006-02-10 2007-08-23 Janssen Pharmaceutica N.V. Novel tricyclic dihydropyrazines as potassium channel openers
US20090176736A1 (en) * 2006-04-20 2009-07-09 Katsumi Dohura Pharmaceutical composition for conformational diseases
CN101528202A (zh) * 2006-07-05 2009-09-09 特瓦制药工业有限公司 美金刚的药物组合物
EP1908748A1 (en) * 2006-10-05 2008-04-09 Krka Process for the preparation of memantine and its hydrochloric acid salt form
BRPI0718437A2 (pt) * 2006-10-27 2013-11-19 Medivation Neurology Inc Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
US20100292341A1 (en) * 2007-06-29 2010-11-18 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
EP2211836A2 (en) 2007-10-10 2010-08-04 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009091932A2 (en) * 2008-01-18 2009-07-23 Adamas Pharmaceuticals, Inc. Treatment of mild dementia of the alzheimer's disease type
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9827200B2 (en) * 2012-04-24 2017-11-28 Daiichi Sankyo Company, Limited Orally disintegrating tablet and production process therefor
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
KR20190076711A (ko) 2017-12-22 2019-07-02 한미약품 주식회사 메만틴을 포함하는 속방성 및 서방성을 동시에 가지는 경질캡슐 제제 및 그 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods

Also Published As

Publication number Publication date
JP2006527774A (ja) 2006-12-07
AU2004249151A1 (en) 2004-12-29
WO2004112768A1 (en) 2004-12-29
PL378902A1 (pl) 2006-05-29
CA2529535A1 (en) 2004-12-29
BRPI0411451A (pt) 2006-07-18
KR20060033727A (ko) 2006-04-19
RU2006101225A (ru) 2006-06-10
US20060251717A1 (en) 2006-11-09
ZA200509379B (en) 2006-11-29
CN1805737A (zh) 2006-07-19
IL172233A0 (en) 2006-04-10
EP1631273A1 (en) 2006-03-08
US20040254251A1 (en) 2004-12-16
MXPA05012810A (es) 2006-02-13
TW200524639A (en) 2005-08-01

Similar Documents

Publication Publication Date Title
NO20055880L (no) Memantin orale doseringsformer
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
RU2010105122A (ru) Композиции для ухода за полостью рта, продукты и способы применения
AR050418A1 (es) Dosificacion fija de anticuerpos her
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
ES2153338T1 (es) Dosificacion mejorada de dosis multiples de medicamentos.
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
DE69920689D1 (de) Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
RU2008122358A (ru) Лекарственные формы, содержащие ag013736
ES2524369T3 (es) Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
KR970025615A (ko) 암 전이 억제제
EA200800075A1 (ru) Схема дозирования для празугреля
KR970061244A (ko) 치매 치료용 약학 조성물
AR036312A1 (es) Composicion farmaceutica
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
BR0115390A (pt) Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
PE20040706A1 (es) Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application